ArticleCell reports. Medicine2025

ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.

Songnan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.